Skip to main content

Advertisement

SpringerLink
Log in

Chronic intestinal pseudoobstruction

  • Published:
Current Treatment Options in Gastroenterology Aims and scope Submit manuscript

Opinion statement

Patients with chronic intestinal pseudoobstruction (CIP) experience a constellation of symptoms including abdominal pain, nausea, fullness, and malaise which fluctuates in severity and invariably result in a diminished quality of life. Though surgical resection or transplantation may be an option for some, there currently is no cure for CIP. Thus, management strategies utilize pharmacologic, intravenous, endoscopic, and surgical techniques to promote transit, minimize painful bloating, reduce complications of stasis, and improve quality of life. Prokinetic agents such as erythromycin, metoclopramide, cisapride, neostigmine, and tegaserod may be effective for acute exacerbations. Octreotide may reduce symptoms of bacterial overgrowth and bloating by stimulating migrating motor complexes. Enteral tubes for venting and nutritional support may reduce hospitalizations. Total parenteral nutrition (TPN), fraught with well-known complications, may be the only tolerated source for nutrients and fluid. Advanced disease may magnify nutritional problems, difficulties of long term intravenous and intestinal access, and poor symptom control. Because the initial process may manifest in other intestinal regions following surgery, resection of involved segments should be performed with caution. Small intestinal transplantation is a high-risk surgery performed in persons unable to tolerate intravenous (IV) nutrition. Optimal management for persons with CIP should not only provide nutritional and symptom focused care but should be part of a supportive network which links patients to their appropriate healthcare needs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. He CL, Burgart L, Wang L, et al.: Decreased interstitial cell of cajal volume in patients with slow-transit constipation. Gastroenterology 2000, 118: 14–21.

    Article  PubMed  CAS  Google Scholar 

  2. Pardi DS, Miller SM, Miller DL, et al.: Paraneoplastic dysmotility: loss of interstitial cells of Cajal. Am J Gastroenterol 2002, 97: 1828–1833.

    Article  PubMed  Google Scholar 

  3. Sodhi N, Camilleri M, Camoriano JK, et al.: Autonomic function and motility in intestinal pseudoobstruction caused by paraneoplastic syndrome. Dig Dis Sci 1989, 34: 1937–1942.

    Article  PubMed  CAS  Google Scholar 

  4. Darnell RB, DeAngelis LM: Regression of small-cell lung carcinoma in patients with paraneoplastic neuronal antibodies. Lancet 1993, 341: 21–22.

    Article  PubMed  CAS  Google Scholar 

  5. Kuemmerle J, Foxx-Orenstein A: Narcotic bowel syndrome. Reg Peptide Letter 1994, 5: 68–69.

    Google Scholar 

  6. Schuffler MD: Chronic intestinal pseudo-obstruction syndromes. Med Clin North Am 1981, 65: 1331–1358.

    PubMed  CAS  Google Scholar 

  7. Faulk DL, Anuras S, Freeman JB: Idiopathic chronic intestinal pseudo-obstruction: use of central venous nutrition. JAMA 1978, 240: 2075–2076.

    Article  PubMed  CAS  Google Scholar 

  8. Mousa H, Hyman PE, Cocjin J, et al.: Long-term outcome of congenital intestinal pseudoobstruction. Dig Dis Sci 2002, 47: 2298–2305.

    Article  PubMed  Google Scholar 

  9. Vassallo MJ, Camilleri M, Sullivan SN, Thomforde GM: Effects of erythromycin on gut transit in pseudoobstruction due to hereditary coproporphyria [Comment]. J Clin Gastroenterol 1992, 14: 255–259.

    Article  PubMed  CAS  Google Scholar 

  10. Minami T, Nishibayashi H, Shinomura Y, Matsuzawa Y: Effects of erythromycin in chronic idiopathic intestinal pseudo-obstruction. J Gastroenterol 1996, 31: 855–859.

    Article  PubMed  CAS  Google Scholar 

  11. Lipton AB, Knauer CM: Pseudo-obstruction of the bowel: therapeutic trial of metoclopramide. Am J Dig Dis 1977, 22: 263–265.

    Article  PubMed  CAS  Google Scholar 

  12. Soudah HC, Hasler WL, Owyang C: Effect of octreotide on intestinal motility and bacterial overgrowth in scleroderma. N Engl J Med 1991, 325: 1461–1467.

    Article  PubMed  CAS  Google Scholar 

  13. Hyman PE, McDiarmid SV, Napolitano J, et al.: Antroduodenal motility in children with chronic intestinal pseudo-obstruction. J Pediatr 1988, 112: 899–905.

    Article  PubMed  CAS  Google Scholar 

  14. Di Lorenzo C, Reddy SN, Villanueva-Meyer J, et al.: Cisapride in children with chronic intestinal pseudoobstruction: an acute, double-blind, crossover, placebocontrolled trial. Gastroenterology 1991, 101: 1564–1570.

    PubMed  Google Scholar 

  15. Hyman PE, Di Lorenzo C, McAdams L, et al.: Predicting the clinical response to cisapride in children with chronic intestinal pseudo-obstruction. Am J Gastroenterol 1993, 88: 832–836. Report of the clinical factors in chronic intestinal pseudoobstruction that predict responsiveness to pharmacologic therapy.

    PubMed  CAS  Google Scholar 

  16. Camilleri M, Balm RK, Zinsmeister AR: Symptomatic improvement with 1-year cisapride treatment in neuropathic chronic intestinal dysmotility. Aliment Pharmacol Ther 1996, 10: 403–409.

    Article  PubMed  CAS  Google Scholar 

  17. Muller-Lissner S, Fumagalli I, Bardhan KD, et al.: Tegaserod, a 5-HT(4) receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating, and constipation. Aliment Pharmacol Ther 2001, 15: 1655–1666.

    Article  PubMed  CAS  Google Scholar 

  18. Novick J, Miner P, Krause R, et al.: A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation. Aliment Pharmacol Ther 2002, 16: 1877–1688.

    Article  PubMed  CAS  Google Scholar 

  19. Degen L, Matzinger D, Merz M, et al.: Tegaserod, a 5-HT4 receptor partial agonist, accelerates gastric emptying and gastrointestinal transit in healthy male subjects. Aliment Pharmacol Ther 2001, 15: 1745–1751.

    Article  PubMed  CAS  Google Scholar 

  20. Prather C, Camilleri M, Zinsmeister AR, et al.: Tegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndrome. Gastroenterology 2000, 118: 463–468.

    Article  PubMed  CAS  Google Scholar 

  21. Mughal MM, Irving MH: Treatment of end-stage chronic intestinal pseudo-obstruction by subtotal enterectomy and home parenteral nutrition. Gut 1988, 29: 1613–1617.

    PubMed  CAS  Google Scholar 

  22. Murr MM, Sarr MG, Camilleri M: The surgeon’s role in the treatment of chronic intestinal pseudoobstruction. Am J Gastroenterol 1995, 90: 2147–2151. Excellent discussion of experience in surgical management of chronic intestinal pseudo-obstruction.

    PubMed  CAS  Google Scholar 

  23. Nayci A, Nayci A, Avlan D, Polat A, Aksoyek S: Treatment of intestinal pseudo-obstruction by segmental resection. Pediatr Surg Int 2003, 19: 44–46.

    Article  PubMed  CAS  Google Scholar 

  24. Pitt HA, Mann LL, Berquist WE, et al.: Chronic intestinal pseudo-obstruction: management with total parenteral nutrition and a venting enterostomy. Arch Surg 1985, 120: 614–618.

    PubMed  CAS  Google Scholar 

  25. Grant D: Current results of intestinal transplantation: the International Intestinal Transplant Registry. Lancet 1996, 347: 1801–1803. Review of the results of intestinal transplantation for chronic intestinal pseudo-obstruction and other disorders.

    Article  PubMed  CAS  Google Scholar 

  26. Foxx-Orenstein AE, Jin JG, Grider JR: 5-HT4 receptor agonists and d-opioid receptor antagonists act synergistically to stimulate colonic propulsion. Am J Physiol 1998, 275: G979-G983. First study to identify that the combination of a 5-HT4 agonist and an opioid antagonist result in a marked increase in colonic propulsion in in vitro studies. It also discusses clinical implications.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Clinical Enteric Neuroscience Translational and Epidemiologic Research Program (C.E.N.T.E.R.), Enteric Neuroscience Program, Charlton 8, Mayo Clinic and Foundation, 200 First Street SW, 55905, Rochester, MN, USA

    Greg Lyford MD & Amy Foxx-Orenstein DO

Authors
  1. Greg Lyford MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Amy Foxx-Orenstein DO
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lyford, G., Foxx-Orenstein, A. Chronic intestinal pseudoobstruction. Curr Treat Options Gastro 7, 317–325 (2004). https://doi.org/10.1007/s11938-004-0018-0

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11938-004-0018-0

Keywords

Search

Navigation